Show simple item record

dc.contributor.authorRusckowski, Mary
dc.contributor.authorFritz, Benjamin
dc.contributor.authorHnatowich, Donald J.
dc.date2022-08-11T08:09:32.000
dc.date.accessioned2022-08-23T16:34:31Z
dc.date.available2022-08-23T16:34:31Z
dc.date.issued1992-10-01
dc.date.submitted2009-03-10
dc.identifier.citationJ Nucl Med. 1992 Oct;33(10):1810-5.
dc.identifier.issn0161-5505 (Print)
dc.identifier.pmid1403148
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38350
dc.description.abstractSince favorable images of infection are obtained with radio-labeled nonspecific IgG, streptavidin has been considered as an alternative protein in this investigation. The advantage of streptavidin is that once localized it may be targeted with radiolabeled biotin. Studies were conducted in a mouse model with an Escherichia coli infection in one thigh. Indium-111-labeled streptavidin showed equivalent localization to the infection as that obtained with 111In-labeled polyclonal nonspecific IgG, however blood levels with streptavidin were lower at all time points; consequently, target-to-blood ratios were improved. Pretargeting with unlabeled streptavidin followed 3 hr later with 111In-labeled biotin showed equivalent localization in the target and reduced activity in all organs sampled. As such, infected thigh-to-normal thigh ratios were improved 3-fold for pretargeting versus either labeled IgG or streptavidin. Improvements in infected thigh-to-liver and blood ratios were greater than 8-fold. Only in the case of kidneys was the ratio unimproved. In conclusion, we have shown that by preadministration of unlabeled streptavidin followed by labeled biotin, infectious lesions in a mouse model may be imaged earlier with lower background levels relative to the administration of labeled nonspecific IgG.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=1403148&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://jnm.snmjournals.org/content/33/10/1810.long
dc.subjectAnimals
dc.subjectBacterial Proteins
dc.subjectBiotin
dc.subjectEdetic Acid
dc.subjectEscherichia coli Infections
dc.subjectImmunoglobulin G
dc.subjectIndium Radioisotopes
dc.subjectLysine
dc.subjectMale
dc.subjectMice
dc.subjectPentetic Acid
dc.subjectRadioimmunodetection
dc.subjectStreptavidin
dc.subjectTissue Distribution
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleLocalization of infection using streptavidin and biotin: an alternative to nonspecific polyclonal immunoglobulin
dc.typeArticle
dc.source.journaltitleJournal of nuclear medicine : official publication, Society of Nuclear Medicine
dc.source.volume33
dc.source.issue10
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1215
dc.identifier.contextkey770193
html.description.abstract<p>Since favorable images of infection are obtained with radio-labeled nonspecific IgG, streptavidin has been considered as an alternative protein in this investigation. The advantage of streptavidin is that once localized it may be targeted with radiolabeled biotin. Studies were conducted in a mouse model with an Escherichia coli infection in one thigh. Indium-111-labeled streptavidin showed equivalent localization to the infection as that obtained with 111In-labeled polyclonal nonspecific IgG, however blood levels with streptavidin were lower at all time points; consequently, target-to-blood ratios were improved. Pretargeting with unlabeled streptavidin followed 3 hr later with 111In-labeled biotin showed equivalent localization in the target and reduced activity in all organs sampled. As such, infected thigh-to-normal thigh ratios were improved 3-fold for pretargeting versus either labeled IgG or streptavidin. Improvements in infected thigh-to-liver and blood ratios were greater than 8-fold. Only in the case of kidneys was the ratio unimproved. In conclusion, we have shown that by preadministration of unlabeled streptavidin followed by labeled biotin, infectious lesions in a mouse model may be imaged earlier with lower background levels relative to the administration of labeled nonspecific IgG.</p>
dc.identifier.submissionpathoapubs/1215
dc.contributor.departmentDepartment of Nuclear Medicine
dc.source.pages1810-5


This item appears in the following Collection(s)

Show simple item record